Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPN1 | P15169 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4290481 | 1.00 | CPN1 (0.41) | CPN1CPB2SIGMAR1DPP7NOS2 | |
| SCHEMBL9341469 | 0.95 | SIGMAR1 (0.39) | CPN1CPB2SIGMAR1GAA | |
| SCHEMBL10608121 | 0.95 | CPN1 (0.41) | CPN1CPB2GAA | |
| SCHEMBL10608177 | 0.89 | CPN1 (0.44) | CPN1CPB2NOS2 | |
| SCHEMBL23709494 | 0.82 | CPN1 (0.40) | CPN1CPB2SIGMAR1DPP7 | |
| SCHEMBL557956 | 0.82 | CPN1 (0.40) | CPN1CPB2SIGMAR1DPP7 | |
| SCHEMBL3937383 | 0.82 | CPN1 (0.46) | CPN1CPB2NOS2 | |
| SCHEMBL9540250 | 0.81 | GAA (0.40) | GAA | |
| SCHEMBL3567805 | 0.81 | CPN1 (0.38) | CPN1CPB2NOS2 | |
| SCHEMBL28035328 | 0.81 | CPN1 (0.42) | CPN1CPB2SIGMAR1DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807078-A1 | DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2007-07-18 | — | — | EP | claimed |
| WO-2006042150-A1 | DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2006-04-20 | — | — | WO | claimed |
| US-20090275581-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090264428-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| EP-0600955-A1 | 5-HT4 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-06-15 | — | — | EP | disclosed |
| WO-1993003725-A1 | 5-HT4 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1993-03-04 | — | — | WO | disclosed |
| EP-0174565-B1 | PIPERIDINE DERIVATIVES AND FUNGICIDAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR COMBATING FUNGI | BASF Aktiengesellschaft (DE) | 1989-10-25 | — | — | EP | disclosed |
| US-4673683-A | Fungicidal piperidine derivatives | BASF AKTIENGESELLSCHAFT (DE) | 1987-06-16 | — | — | US | disclosed |
| EP-0174565-A2 | Piperidine derivatives and fungicidal compositions containing them, and process for combating fungi | BASF Aktiengesellschaft (DE) | 1986-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275581-A1 | RENIN INHIBITORS | REN, ACE, SERPINB1 | CPN1 63/4885CPB2 31/4885SIGMAR1 4124/4885 |
| US-20090264428-A1 | Renin Inhibitors | REN, ACE, SERPINB1 | CPN1 55/4885CPB2 31/4885SIGMAR1 4481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.